A longitudinal study of biochemical variables in women at risk of preeclampsia

American Journal of Obstetrics and Gynecology

Volumn 187, Issue 1, 2002, Pages 127-136

  Chappell, Lucy C ^a   Seed, Paul T ^a   Briley, Annette ^a   Kelly, Frank J ^a   Hunt, Beverley J ^a   Charnock Jones, D Stephen ^b   Mallet, Anthony I ^c   Poston, Lucilla ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

Oxidative stress; Placenta; Prediction; Preeclampsia

Indexed keywords

ASCORBIC ACID; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; URIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; ENDOTHELIUM; FEMALE; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PLACENTA; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; RISK FACTOR; SMALL FOR DATE INFANT;

EID: 0036071320     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2002.122969     Document Type: Article

References (25)

1. Maternal mortality: Confidential enquiries into maternal deaths in the United Kingdom
2. Prediction and differential diagnosis
3. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: A randomised trial
4. Assessment of uterine arterial notching as a screening test for adverse pregnancy outcome
5. The classification and definition of the hypertensive disorders of pregnancy
6. Customised antenatal growth charts
7. Evidence for increased oxidative damage in patients with cystic fibrosis
8. Time course of vitamin E repletion in the premature infant
9. Analysis of F2 isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: Development of a solid-phase extraction procedure
10. Longitudinal analysis using generalized linear models
11. Oxidative stress in the pathogenesis of preeclampsia
12. Plasma and urinary 8-isoprostane as an indicator of lipid peroxidation in preeclampsia and normal pregnancy
13. Circulating markers of oxidative stress are raised in normal pregnancy and preeclampsia
14. Hyperuricemia and xanthine oxidase in preeclampsia, revisited
15. Lipid metabolism and oxidative stress
16. Placental leptin
17. Augmented placental production of teptin in pre-eclampsia: Possible involvement of hypoxia
18. Does leptin exhibit cytokine-like properties in tissues of pregnancy?
19. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and pre-eclampsia
20. Pre-eclampsia is associated with reduced serum levels of placenta growth factor
21. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia
22. Placenta growth factor is not an early marker for the development of severe preeclampsia
23. Regulation of placental endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen: A review
24. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in uterine growth retardation: Possible markers of placental function
25. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole